Results 101 to 110 of about 39,758 (253)
The future of pharmacogenetics in the treatment of heart failure [PDF]
, 2015 Heart failure is a common disease with high levels of morbidity and mortality. Current treatment comprises β-blockers, ACE inhibitors, aldosterone antagonists and diuretics.
Alex S Doney +11 more
core +2 more sources
A trombocita aggregáció gátló kezelés monitorozásának klinikai relevanciái perkután koronária intervención átesett betegek körében [PDF]
, 2009 10
Aradi Dániel
core
Reduction in Recurrent Cardiovascular Events with Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes from the TRITON-TIMI 38 Trial [PDF]
, 2011 Aims: In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS ...
Antman, Elliott Marshall +8 more
core +1 more source
Brazilian Journal of Cardiovascular SurgeryObjective: The aims of this study were to determine whether the detection of preoperative clopidogrel resistance in patients undergoing cardiac surgery while using clopidogrel could play a guiding role in the prediction of postoperative excessive ...
Mehmet Kizilay +5 more
doaj +1 more source
Long-term outcomes of omniflow II biosynthetic vascular graft in lower extremity arterial revascularization [PDF]
, 2018 Background: This study aims to evaluate the patency rates and long-term outcomes of femoro-popliteal bypass procedures with Omniflow II biosynthetic vascular grafts in patients with occlusive vascular disease.
Göncü, M.T. +4 more
core +1 more source
Diabetes mellitus and clopidogrel “resistance”
Clinical Management Issues, 2015 In our Department arrives a 75-year-old patient with hypertension, diabetes mellitus (DM) treated with hypoglycaemic drugs, dyslipidaemia and ischaemic heart disease post-acute myocardial infarction treated with triple coronary artery bypass surgery and subsequent percutaneous transluminal coronary angioplasty (PTCA).
Massarelli, Laura +3 more
openaire +4 more sources
Clopidogrel Resistance in Stroke Cases
Istanbul Medical Journal, 2019 Introduction:Clopidogrel treatment is one of the standard treatments in terms of reducing mortality and morbidity in patients with cerebrovascular disease diagnosed with large artery atherosclerosis. However, resistance to clopidogrel treatment is a significant problem today. In this study, we aimed to retrospectively investigate clopidogrel resistance
Nihan Çarçak +4 more
openaire +2 more sources
New in vitro effects of clopidogrel on platelets in hyperlipidemic and healthy subjects [PDF]
, 2010 Objective: We aimed to detect novel in vitro effects of clopidogrel on platelets by assessment of the following parameters: malondialdehyde, glutathione, nitrite, aggregation response, and expressions of P-selectin, fibrinogen, apolipoprotein A1 ...
Azize Şener +5 more
core +2 more sources
Clopidogrel Resistance: Current Issues
Journal of Enam Medical College, 2016 Antiplatelet agents are mainly used in the prevention and management of atherothrombotic complications. Dual antiplatelet therapy, combining aspirin and clopidogrel, is the standard care for patients having acute coronary syndromes or undergoing percutaneous coronary intervention according to the current ACC/AHA and ESC guidelines.
openaire +2 more sources